Menu

ISTOCK, KKOLOSOV

Effort to Reproduce Cancer Studies Scales Down to 18 Papers

The Reproducibility Project: Cancer Biology initially aimed to replicate the results of 50 high-impact research articles.

Aug 1, 2018
Diana Kwon

A large effort to reproduce high-impact cancer research has scaled down the number of studies it plans to replicate from 50 to 18, Science reported yesterday (July 31). 

The Reproducibility Project: Cancer Biology (RP:CP) was launched by the Center for Open Science and Science Exchange, a biotechnology company, in 2013. The project’s initial aim was to replicate experiments from 50 high-profile cancer papers published between 2010 and 2012. Starting in 2015, however, organizers began to pare down the number of papers due to budgetary and resource constraints. 

See “Replication Complications

“I wish we could have done more,” Tim Errington, a biologist who runs RP:CP from the Center for Open Science, tells Science. “There is an element of not truly understanding how challenging it is until you do a project like this.”

Hurdles to replicating experiments included a lack of detailed protocols and easily obtainable reagents. “Communication and sharing are low-hanging fruit that we can work on to improve,” Elizabeth Iorns, the president of Science Exchange, tells Science. 

To date, RP:CP has published 10 of the 18 replication studies in eLife. Two of the studies failed to replicate and two were inconclusive; project members were able to reproduce at least parts of the experiments from the remaining six. According to Science, the original findings from many of the 50 papers RP:CP planned to replicate have already been confirmed by other independent groups. 

RP:CP also decided to discontinue 11 ongoing replication efforts, but plans to publish the findings from those incomplete studies. 

See “Latest Reproducibility Project Study Fails to Replicate

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

Horizon Discovery introduces Myeloid DNA Reference Standard to support genetic testing of leukemia

Horizon Discovery introduces Myeloid DNA Reference Standard to support genetic testing of leukemia

Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, today announced the launch of its Myeloid DNA Reference Standard. The first-to-market large cell-line derived myeloid cancer reference standard designed enables faster, more reliable and more cost-effective assay validation, to support the market in bringing routine testing into practice.

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!